Account
Newsletter
17.02.2023
PMA Insights: Week 7

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Articles
17.02.2023
How will governments face the cost of medical mira...

Among the most expensive therapies are gene therapies that show promise to transform inherited disor...

Read more
Insider Insights
09.02.2023
New criteria for ATMPs which must follow quality r...

The Federal Joint Committee (G-BA) has set out criteria for ATMPs which are likely to require qualit...

Read more
Newsletter
02.02.2023
PMA Insights: Week 5

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Insider Insights
02.02.2023
NICE has recommended Yescarta as the first CAR T-c...

NICE has recommended the first CAR T-cell therapy, Yescarta for the treatment of some lymphomas in a...

Read more
Insider Insights
25.01.2023
AstraZeneca/Daiichi Sankyo’s Enhertu has been re...

NICE have recommended Enhertu for the treatment of HER2-positive breast cancer within a managed acce...

Read more
Articles
11.01.2023
What are the 5 Pricing & Market Access trends ...

Our experts provide an overview of the five key trends that could shape the pricing and market acces...

Read more
Newsletter
04.01.2023
PMA Insights: Week 1

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Newsletter
15.12.2022
PMA Insights: Week 50

We summarise four handpicked articles from pharmaceutical, pricing and market access that are worth ...

Read more
Articles
14.12.2022
2022 Review: Effective P & R Processes to Ens...

We discuss gene therapy pricing and reimbursement, manufacturing methods, analytical analysis, and k...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.